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Abstract
Dilated cardiomyopathy involves enlargement of the ventricular chamber 
and systolic dysfunction. The reduction in quality of life and increased levels of 
congestive heart failure, combined with the high diagnosis rate within the canine 
population, highlights the need for research into this disorder. This chapter looks 
at prevention, diagnosis, prognosis, and treatment of dilated cardiomyopathy. It 
details the disease pathology and physiology through to present clinical practices 
and studies to support prevention and treatment. This chapter also looks at the 
research being undertaken to further understand cardiomyopathies in dogs and 
develop new interventions. This ranges from fatty acids profiles to genetics and 
even personalized medicine and comparisons with human cardiomyopathy.
Keywords: Dilated cardiomyopathy (DCM), Canine, Echocardiography,  
Holter Monitoring
1. Introduction
DCM is characterised by ventricular chamber enlargement and systolic dys-
function which often leads to congestive heart failure [1]. The aetiology of DCM is 
complex. Genetic factors, myocardial ischemia, hypertension, toxins, infections 
and metabolic defects have been implicated [2]. DCM is the most common specific 
heart disease diagnosis within the Swedish insured canine population, following the 
more general diagnosis of cardiomyopathy, accounting for 10% of the cardiac diag-
noses [1]. Prevention of disease requires a thorough understanding of the underly-
ing causes of disease. Where the causes of disease are understood it can allow for 
modifications in diet, behaviour, and/or preventative medicine to be prescribed, or 
risk-reducing surgery to be undertaken where appropriate [3–5]. The underlying 
causes of non-communicable diseases are varied, with a wide range of environmen-
tal and genetic factors contributing to disease [6–11]. In most cases a combination 
of interacting factors contribute to disease risk, initiation, and progression [12–15].
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2. Diagnosis and prognosis of canine cardiomyopathy
Dilated cardiomyopathy (DCM) is a significant cause of congestive heart failure 
in dogs, characterised by the enlargement and impaired contraction of the left or 
both ventricles [1–3]. The development of DCM can be classified into three main 
stages [4, 5]. In Stage 1, the heart appears normal, with no clinical evidence of heart 
disease and often includes dogs that are genetically predisposed to DCM [6]. Stage 
2 (the preclinical or occult phase) is characterised by morphological and electrical 
cardiac changes with a prolonged period without overt clinical symptoms. Stage 
3 (the overt phase) includes clinical signs of congestive heart failure [1–3, 7]. It 
should also be noted that adult DCM clinical signs can vary between breeds.
The gold standard approach to DCM diagnosis relies on echocardiographic 
and 24-hour electrocardiographic (ECG) assessments (Figure 1), in conjunction 
with monitoring clinical presentation and signalment [7–9]. The most common 
early clinical signs include exercise intolerance and heart murmurs/irregular heart 
rhythms. As the condition develops pulmonary congestion edema may develop and 
abdominal fluid accumulation and/or pleural effusion may be present. Notable 
other signs including weakness, inappetence, weight loss, breathlessness, cough-
ing, increased breathing rate, collapse and lethargy are more frequent in dogs with 
heart failure caused by DCM, as is sudden death [3]. Congenital or acquired cardiac 
diseases with similar presentations to DCM must be also be excluded [10, 11].
Figure 1. 
A) Six lead ECG showing fast atrial fibrillation in a dog with dilated cardiomyopathy (DCM). Motion-mode 
echocardiogram from dogs that were classified as B) clinically normal, C) DCM showing dilation of the left 
ventricle and irregular filling associated with atrial fibrillation, D) DCM showing dilation of the left ventricle 
and a sinus tachycardia, and E) DCM (Left) alongside a motion-mode echocardiogram from a normal dog 
(Right), note the difference in the size of the ventricles and the amount of movement in the walls.
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Echocardiography is used to assess left ventricular (LV) dimensions and 
function, where a dilated ventricle, based on M-mode or 2D measurements, 
with reduced contractility is indicative of DCM [9, 12]. M-mode is a time motion 
technique displaying the movement of structures over several cardiac cycles along 
a specific plane [13, 14]. The use of M-mode in conjunction with ECG allows LV 
measurements to be made more reliably (see Figure 1 for examples). The LV 
end-diastolic internal diameter (LVIDd) should be measured during the onset of 
the QRS complex and near the end of the T wave for LV internal dimension dur-
ing systole (LVIDs) [15]. Comparisons are ideally made against breed-specific LV 
measurements, but where this is not possible values should be compared to breeds 
of a similar size and weight [9].
Fractional shortening is a major indicator of systolic function, where values less 
than 20–25% suggest impaired contractility. This is calculated as follows:
 ( )FS LVIDd LVIDs /LVIDd X= −   100  (1)
In some cases, fractional shortening may be misleading, for example in athletic 
breeds values may appear to be lower, and in dogs with severe mitral regurgitation 
they can be higher [2, 15, 16], therefore caution is recommended when making a 
diagnosis. End point to septal separation (EPSS) is the minimum distance between 
the anterior mitral leaflet (E point) to the LV septal wall, during the rapid filling 
phase of diastole [17, 18]. An EPSS measurement of >10 mm in any breed is consid-
ered abnormal. Increased values can occur in volume overload or reduced fractional 
shortening resulting in LV dilation [11, 13].
A characteristic feature of DCM is the ventricular chamber becoming more 
spherical as the ventricle dilates [19]. The index of sphericity (SI) is calculated 
during diastole by dividing the LV length with the LV width, where a value <1.65 is 
indicative of an abnormally rounder chamber [10].
Although M-mode echocardiography is commonly used (Figure 1), its one-
dimensional nature restricts the spatial information provided and the technique 
is reliant on geometrical assumptions that may be altered during pathological 
states [8, 14, 20, 21]. The American Society of Echocardiography recommends that 
linear measurements should not be used to calculate LV volume, and suggest that 
the biplanar Simpson’s methods of discs (SMOD) is more suitable [22]. A study in 
Dobermans concluded that SMOD is more sensitive than M-mode in detecting early 
echocardiographic changes observed in DCM. Thus, it is recommended that where 
possible, SMOD reference values should be used [8, 10].
The SMOD volume formula is based on tracing the endocardial border across 
the mitral annulus and measuring the long axis of the left ventricle. The LV cavity 
is divided into 20 discs of equal height, where the cross-sectional area of each disc 
is based on the diameters obtained from two orthogonal LV views. End-diastolic 
(EDV) and end-systolic (ESV) volumes are calculated from the summation of the 
stacked discs, often utilising the software available on many ultrasound machines. 
These volumes can be normalised to body surface area to give volume indices 
(EDV-I and ESV-I). The current recommendations are that an ESV-I > 80 ml/m2 is a 
strong indication of systolic dysfunction [2, 8, 22]. Ejection fraction (EF) is calcu-
lated in a similar way to fractional shortening, but volume measurements are used 
as follows:
 ( )EF EDV ESV /EDV= −  (2)
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Thus, EF takes into account both radial and longitudinal cardiac changes, where 
dogs with EF <40% are reflective of reduced inotropy [2, 22].
ECG is used for the detection of arrhythmias but, as arrhythmias are often inter-
mittent, they may be missed by an in-house 5-minute ECG commonly used in first 
opinion practice. 24-hour ambulatory ECG (Holter) monitoring provides a more 
representative assessment, where the patient is not restricted to a clinical setting, 
yet continuous monitoring is enabled [11, 23]. Holter monitoring for 24 hours is 
often used to identify individuals that have arrhythmias, with ventricular arrhyth-
mias being common in animals [88]. Owners additionally record activities such as 
sleeping or running to enable changes in heart rate or rhythm to be correlated with 
patient activity [24]. Most dogs with DCM show evidence of arrhythmias and in 
certain breeds these may precede echocardiographic abnormalities [25, 26].
Atrial fibrillation (AF) is a common supraventricular tachyarrhythmia in 
large and giant breeds [3, 27]. Despite the presence of AF in a large percentage 
of dogs with DCM, the mechanistic and clinical relationship between DCM and 
AF has not been clarified [16–19]. Figure 1A shows an example of a six lead ECG 
showing fast atrial fibrillation in a dog with DCM. One canine study showed that 
80.5% of individuals with DCM also had a diagnosis of AF [20], with another 
study showing occurrence in 87.6% of the patients [19]. Most individuals were 
diagnosed with AF at the same time as DCM or in the 2 years prior to the diagno-
sis of DCM, which indicates that AF may be a precursor to a clinical diagnosis of 
DCM [20]. Therefore, individuals diagnosed with AF should be carefully moni-
tored and regularly presented for heart testing to check for DCM. There is the 
potential to improve the survival of individuals diagnosed with AF by treating 
them with drugs such as pimobendan prior to the development of DCM or heart 
failure [21].
Ventricular premature complexes (VPC) appear to be more common in 
the Doberman and Boxer breeds than other breeds. In Dobermans, >300 
VPCs/24 hours, or two successive Holter recordings within one year showing 
between 50 and 300 VPCs/24 hours is considered diagnostic for preclinical DCM, 
even if echocardiographic findings appear normal [10]. Thus, Holter monitoring is 
useful in identifying Dobermans that are destined to develop DCM. Similar diag-
nostic reference ranges are lacking in the Boxer but >50 VPCs/24 hours would be 
considered to be abnormal [2].
The European Society of Veterinary Cardiology (ESVC) has proposed a scor-
ing system to aid in the diagnosis of DCM, especially for dogs that present with 
equivocal findings. The following cardiac changes fall into the major criteria and 
are allocated 3 points each: (i) LV enlargement, (ii) reduced systolic function, and 
(iii) increased LV sphericity. The remaining findings are considered minor (1 point 
each): (a) arrythmias in specific breeds; (b) AF; (c) increased EPSS; (d) increased 
pre-ejection period: ejection time ratio; (e) LV fractional shortening in equivocal 
range; (f) left or biatrial enlargement. A total of ≥6 points is indicative of DCM 
and a score of 1–5 should encourage repeated examination for evidence of disease 
progression [2].
Annual screening using echocardiography and Holter monitoring, has been 
recommended for breeds genetically predisposed to DCM, including Dobermans, 
Boxers, Newfoundlands, Great Danes and Irish Wolfhounds (IWH). Detection of 
the pre-clinical phase allows earlier therapeutic intervention, can improve progno-
sis, and enables the removal of affected dogs from breeding programmes if appro-
priate [10, 28, 29]. This is particularly important in Dobermans as 30% die suddenly 
prior to the onset of congestive heart failure [30, 31]. However, yearly testing can 
be expensive as it often requires referral to specialists thus restricting accessibility. 
In some countries, breed groups/welfare groups have set up testing programmes, 
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and some even support these financially or fundraise, due to the concern about the 
numbers of animals developing cardiovascular problems.
Given the complex nature of diagnosis, that gold standard tests may not 
always be available for every client, and the financial restraints faced by some 
owners, development of further and/or potentially cost effective diagnosis tools 
are always needed [5, 7]. Biomarkers such as N-Terminal pro B-type natriuretic 
peptide (NT-proBNP) have been used in humans to identify patients with occult LV 
dysfunction. The NT-proBNP assay is useful to differentiate between cardiac and 
non-cardiac causes of respiratory distress, where conventional testing alone could 
lead to ambiguous results [28, 32]. In a study of 328 Dobermans, those that had 
plasma concentrations of NT-proBNP >400 pmol/L, in the absence of renal dys-
function, were more likely to have echocardiographic abnormalities. However, the 
results cannot be considered diagnostic as NT-proBNP concentrations overlapped 
in groups of dogs with and without preclinical DCM [7, 33]. The use of in-house 
5-minute ECG has reasonable specificity and in Dobermans the detection of 1 VPC 
strongly suggests that >100 VPC would be recorded via Holter. However, due to 
poor sensitivity, absence of VPC should not rule out the possibility of DCM [6, 23]. 
The emphasis is that the results from these tests should not be used to establish a 
diagnosis, but rather to identify dogs that would benefit further from more costly 
diagnostic tests [34].
Two histopathological variations of canine DCM have been identified: “attenu-
ated wavy fibre type” and “fatty infiltration type” [22] indicating that differing 
types of canine DCM exist. The fatty infiltration type has only been reported in 
Doberman Pinschers, Estrela mountain dogs, Great Danes, and Boxers [22–25]; 
whereas the wavy fibre type can occur in all breeds [22, 23]. As the wavy fibre type 
is found across breeds, and in many individuals, it could be the tissue’s response to 
the other processes of DCM. In general, atrophy, or attenuation, of muscle fibres 
is often a result of processes that prevent normal contractile ability: contractile 
ability is consistently compromised in DCM [26]. The clinical relevance and 
prevalence of these two histopathological variants remain to be established, and 
as post mortem tissue is required presently for phenotypic analysis this may not 
be useful in a clinical setting but could provide valuable research insights into the 
disorder [27].
The long-term prognosis of canine DCM can be highly variable, with well man-
aged dogs maintaining a good quality of life for many years and others dying within 
weeks of diagnosis despite careful clinical management [19, 28, 29]. There are some 
breed specific prognosis trends such as Doberman Pinschers which generally have 
a poor prognosis. Their mean time to death (from diagnosis) is in the range of 7.4 to 
9.7 weeks [29, 30], which is low in comparison to other breeds reported to be about 
four times that at 34 weeks [29]. Doberman Pinschers also had the lowest upper 
quartile range for survival time in a study, but analysis carried out by the same 
research showed that Great Danes also suffer from a poor prognosis, with the lowest 
median survival time of any breed [17, 28].
Age of onset can also affect prognosis and may be a useful indicator that differ-
ing types of canine DCM exist. Portuguese water dogs have a specific juvenile form 
of DCM, where age of onset is measured in weeks from birth [31, 32], while in most 
other cases age of onset is measured in years [17]. Great Danes have a mean age of 
onset of 4.8 (SD ± 2.3) years [33], comparable to Irish Wolfhound mean age of onset 
of 4.40 (SD ± 2.03) years [34]; but lower than Doberman Pinscher’s at 7.3 years in 
males and 8.6 years in females [30]. Once identified, knowledge about the differing 
canine DCM types could benefit current and future potential treatments in addition 
to elucidating other clinically important factors in canine DCM, such as longevity 
and prognosis.
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3. Treatment and management options
The ultimate aim of treatment is to cure disease, but this is currently not always 
possible. When a cure is not available, treatment of disease is aimed at reducing 
the impact of the disease, extending lifespan, and maintaining quality of life. 
Treatment of DCM in people is focused primarily on managing symptoms if at the 
overt stage of disease or, if presented with a preclinical case, prolonging the time 
between diagnosis and congestive heart failure [35]. Due to the predisposition of 
certain canine breeds, preclinical cardiac screening can help diagnose early abnor-
mal findings, leading to a more successful diagnosis and potentially a management 
and treatment regime [36], in addition to possibly altering breeding programmes 
and preferences for some owners/breeders.
As with human DCM, in veterinary cases the ultimate aim is to minimise the 
effect of heart failure with attempts to delay disease progression depending on 
the stage of diagnosis [37]. Strategic treatments presently include vasodilators, 
angiotensin-converting enzyme (ACE) inhibitors, diuretics and positive inotropes. 
With atypical breeds or American cocker spaniels and Golden retrievers, dietary 
supplementation of taurine and L-carnitine is usually recommended if the suspected 
aetiology of DCM is diet-related [38–40].
In regards to treating earlier stages of DCM, there is often a focus on the preven-
tion of further myocardial dysfunction by using the cardioprotective effect of ACE 
inhibitors [41]. These interventions focus on the vasodilation of blood vessels by 
reducing angiotensin II effects within the renin-angiotensin-aldosterone system 
(RAAS), a system heavily associated with severe heart disease through aldosterone 
release [42]. ACE inhibitors currently approved for veterinary purposes include 
benazepril, enalapril, imidapril and Ramipril, with the former being used to treat 
initial stages of heart failure and the latter three for more progressive stages [43].
Furosemide and spironolactone are both recommended diuretics, with the for-
mer inhibiting the re-absorption of sodium and chloride in the thick ascending loop 
of Henle to promote natriuresis. The latter is a weak potassium-sparing diuretic 
which works as an aldosterone antagonist. Monotherapy of these diuretics are not 
recommended [44] as they reduce plasma volume, further stimulating RAAS activ-
ity [42]. Therefore, diuretics are often used in combination with ACE inhibitors.
In Ref. to the undetermined link between canine DCM and atrial fibrillation 
(AF), for these patients, positive inotropes such as digoxin are particularly effective 
by increasing vagal tone, hence, decreasing heart rate [45]. Another drug often used 
is diltiazem, a calcium channel blocker also slowing conduction through the atrio-
ventricular node. Although it is in fact a negative inotrope, it is particularly effective 
in dogs with AF by increasing diastolic filling time and therefore improving cardiac 
output [46]. Even though both of these drugs can be used individually, research 
indicates that using these drugs in combination can prove to be more effective [47]. 
With digoxin having a narrow therapeutic index, digoxin toxicity can occur and 
gradual withdrawal should take place if clinical signs such as depression, anorexia 
and vomiting are seen [45]. In addition, pimobendan has been investigated in rela-
tion to prolonging the onset of coronary heart failure due to DCM by having similar 
effects to digoxin whilst advantageously keeping myocardial oxygen demand to a 
minimum [42]. Pimobendan has also been shown to increase the survival rate in 
Dobermans [36] and we can assume it offers similar benefits to other breeds.
Although the majority of canine DCM treatments focus on managing the 
condition whilst optimising quality of life, diet-associated DCM can be potentially 
reversible with certain supplements such as taurine and L-carnitine [40]. Taurine 
deficiency is a prime cause of DCM in cats, evidence suggests micronutrient 
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shortages (e.g. selenium, iron) are linked to human DCM, and there are some trials 
suggesting there may be a link in certain canine breeds, including American cocker 
spaniels, Golden retrievers [38, 40]. Accumulating research indicates that nutrient 
imbalances may cause or exacerbate DCM due to reduced myocardial expenditure 
[48]. There are minimal to no side-effects of taurine supplementation in dogs [49], 
therefore treating American cocker spaniels, Golden retrievers and atypical breeds 
presenting with DCM with taurine pending the results of blood testing may be 
prudent. Furthermore, alongside nutraceuticals such as taurine and L-carnitine, 
omega-3 fatty acids have been shown to significantly reduce muscle loss and prosta-
glandin E2 production, and these results also correlate with increased survival rate 
[50]. However, these supplementary products are very expensive, especially when 
prescribed for larger breed dogs, so finding the possible aetiology for the disease is 
vital to determine the efficacy of these products [49].
Beta-blockers such as carvedilol have shown to have positive impacts for people 
with DCM [51–53]. Although carvedilol is a popular choice in humans with DCM 
and congestive heart failure [54, 55], there is limited evidence to date that these 
are beneficial in canine breeds with DCM [56]. Where used, careful monitoring 
should be ensured and treatment is best tolerated in dogs during the early stages of 
DCM [42].
In latter stages of DCM, the last resort for treating human heart disease includes 
transplants or inserting cardiac assist devices such as pacemakers [37], but these are 
far less realistic for canine patients due to cost, disease prognosis and surgical risk 
for the animal. Therefore, medical management based on symptomatic relief is the 
only current option for these patients [37].
Given that identifying, preventing, managing, and treating canine DCM is still 
a clinical challenge, new approaches are still needed. One new approach focusses 
on therapeutic gene transfer to target underlying molecular defects of ventricular 
dysfunction. Gene therapy could replace a defective gene, or part of a gene, with a 
functional one, resulting in effective amounts of a certain protein being produced 
that was once deficient [57, 58]. Evidence suggests Ca2+ handling is damaged in a 
heart with cardiac failure, and experiments involving altering calcium-handling 
protein levels in rodents through cardiac gene therapy have been successful [59]. 
Although achieving myocardial transduction in larger animal models presents 
many difficulties, therapeutic gene transfer may be a viable option in the future to 
treat canine DCM regardless of underlying cause. Another example of gene therapy 
is the use of vascular endothelial growth factor-B167 (VEGF-B167), which was 
administered via an intracoronary route in a study of 10 dogs with DCM [60]. The 
method was well tolerated by the canine patients. VEGF-B has anti-apoptotic and 
cardioprotective effects, so could be used to mitigate progression of DCM. Naturally 
many genes are associated with cardiomyopathy or in the drug and gene pathways 
[27, 61, 62], and additionally multiple genetic associations have been associated 
with the disorder [20] which potentially increases the complexity of gene therapy 
interventions.
Another of the requirements of gene therapy is understanding which mutations 
cause DCM in which species/breeds, therefore large trials are necessary in order to 
understand the basics, in addition to understanding the best methods of introduc-
ing gene therapy itself. For example gene therapy trials into dystrophin delivery via 
viral vectors has been promising but cardiovascular tissue is more complex than 
skeletal muscle, even when delivered via intravenous injection in dogs [63, 64]. 
Therefore gene therapy may be a very promising avenue of research, but the impact 
of gene associations and delivery methods may need to be taken into account for 
differing individuals and/or breeds.
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Other new approaches being researched currently include myocardial regenera-
tion therapies such as the use of resident cardiac stem cells, bone marrow stem cells, 
and skeletal myoblasts via transplantation therapies [65]. Cellular cardiomyoplasty 
has been explored via transplants of skeletal muscle cells into myocardium of canine 
DCM hearts. In early trials three of five dogs died early of tachyarrhythmias and 
pulmonary embolism, however two dogs survived and showed improved function 
of the heart [66]. Further investigation into this method is needed to understand 
the mechanisms and to prove if it can be successfully used in the clinic. Previous 
research on hamsters using smooth muscle cell transplants also showed clinical 
improvement in heart function [67], therefore this method could be developed for 
dogs and other species.
The use of cardiosphere-derived stem cells (CDCs) from adult dog hearts has 
also been trialled [68]. These cells can differentiate into cardiomyocytes in vitro 
and a study in Doberman pinschers diagnosed with DCM detailed patients given an 
infusion of canine CDCs via the coronary vessels [68, 69]. There was no rejection 
of the cells, and no adverse reactions were reported [69]. It has been suggested that 
therapy using CDCs can slow down ventricular enlargement and the effects of DCM 
such as systolic dysfunction. Studies on larger sample sizes need to be undertaken.
2-deoxyadenosine triphosphate (dATP) is an energy substrate that can be used 
by myosin instead of ATP during formation of cross-bridges in myocardial contrac-
tion. A study discovered that substituting ATP with dATP in both normal and DCM 
hearts leads to increased activity of myofilaments and increased systolic function 
[70]. Another potential pharmaceutical method is active myosin using drugs such 
as danicamtiv, which has undergone in vitro and in vivo trials in dogs, people and 
other mammals [71].
Transvenous electrical cardioversion of AF involves the placement of electrode 
coils in the vasculature of the heart, with the right atrium acting as the anode, and 
the left pulmonary artery acting as the cathode. A connection with a defibrillator 
is made and electrical shocks are given in time with the R wave. In a study of two 
canine cases affected by DCM, treatment resulted in the heartbeat returned to a 
normal sinus rhythm [72]. There is therefore potential for this therapy to be used to 
reduce the risk of AF leading to DCM development.
4. Genetics of cardiomyopathy and association with other conditions
Despite known pre-dispositions to diseases in the majority of UK kennel club 
registered breeds, there are currently only 93 disease associated variants identi-
fied and only 61 genetic tests commercially available across all breeds [73–75]. In 
human genetic testing there are tests available for 10485 conditions [76, 77]. This is 
a large difference despite close similarity between many diseases affecting dogs and 
humans [78–80]. Many tools have been utilised when identifying genetic variants 
associated with human diseases, these include genome wide association studies, 
candidate gene studies, whole exome sequencing, and whole genome sequencing 
[81–84]. These tools have also been utilised to some extent in some canine stud-
ies, but these approaches are often restrictively expensive for companion animal 
studies with limited funding available [85, 86]. The cost of these methods is delay-
ing their clinical and research application in evaluating the genetic basis of canine 
diseases. Identification of susceptibility loci for these diseases has the potential to 
bring improvements in diagnosis and may lead to improved treatments in line with 
diseases which already have genetic loci associated with them [87–92].
The development and progression of common non-communicable diseases 
such as heart disease are influenced by a combination of risk factors. It has 
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been shown in several diseases that interactions between environmental and 
genetic risk factors are important in the development and progression of disease 
[13, 15]. Environmental risk factors for people with DCM are often modifiable 
as individuals can make informed choices with regards to lifestyle changes to 
reduce their risk of developing disease [7, 10, 93], likewise dog owners may be 
able to modify environmental risk factors for their animals. Currently genetic 
risk factors are not modifiable, although genome editing technologies may 
allow this in the future [94]. Despite this, individuals identified as having a high 
genetic risk of developing a disease are currently able to reduce their risk of 
developing disease. Options available include making lifestyle changes to reduce 
other risk factors, increased disease surveillance, and prophylactic medicine 
and surgery [4, 7, 10, 92, 93, 95, 96]. Increased disease surveillance can allow for 
early disease detection and therefore early treatment, which is associated with 
improved prognosis [87, 92]. An additional benefit of knowledge of the underly-
ing genetic cause of disease is that it could lead to targeted treatments such as 
rectifying the defective gene or drugs targeting affected pathways [88, 89].
There are over 50 genes associated with DCM in people, some with multiple 
mutations, whereas there have only been 10 loci associated with canine DCM  
[85, 86, 97–100]. We have recently reviewed the genetics of canine and human 
DCM [27]. There has also been a RNAseq study examining the difference in 
expression of genes between canine DCM hearts and non-DCM hearts [101]. In 
the RNAseq study, genes involved in cellular energy metabolism were expressed 
less in the DCM hearts than the non-DCM hearts [101]. In several breeds canine 
DCM has been shown to be heritable [29, 31, 34]. To date mutations in only two 
genes (PDK4 and STRN) and a single nucleotide polymorphism (SNP) on chro-
mosome 5 have been associated with canine DCM [85, 97, 98, 102], and these are 
limited to a few breeds, suggesting additional genetic causes remain unknown. Of 
note are also cardiac troponin T and dystrophin which have both been highlighted 
in people, dogs and other species in relation to dilated cardiomyopathy [103–105], 
as mentioned in relation to gene therapy trials.
Genetic models and studies have also shown sex-linked genetic influences in 
relation to pathogenesis and a multigenic contribution to canine DCM [102]. The 
work showed that by combining three factors (PDK4, Chr5 TIGRP2P73097 SNP 
and an X-linked locus) DCM incidence could be more accurately predicted in a 
canine population. Overall this data showed that models incorporating multiple 
factors were more effective than those incorporating a single factor [102]. This has 
implications for future studies of the genetics and management of DCM, including 
monitoring which could enable earlier clinical intervention of individuals who are 
high risk.
In addition to commonly being diagnosed with DCM, IWHs are frequently 
diagnosed with atrial fibrillation (AF) [16, 19]. Despite the presence of AF in a large 
percentage of dogs with DCM, the mechanistic and clinical relationship between 
DCM and AF has not been clarified [16–19]. IWHs can develop DCM without AF, 
though it seems that <2% of IWHs with AF do not go on to develop DCM [16, 19]. 
If AF is a potential precursor to DCM, the time from diagnosis of AF to DCM is 
important, as if it is several years than the presence of AF could be less of a concern 
than if it is merely a few months. Also, if AF is a precursor to DCM, there is the 
potential to give individuals diagnosed with AF drugs such as the phosphodiesterase 
III/calcium sensitizing drug, pimobendan, to improve survival [21]. In addition to 
the potential clinical implications of AF diagnosis, if AF can be shown to be related 
to DCM, both diagnoses can be used for genetic association testing. This also has 
implications for individuals included in the unaffected group for genetic association 
testing, as individuals included in the unaffected group must be free of both DCM 
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and AF. There is some evidence that males are affected by DCM more often, or 
earlier in life than females [16, 18, 20, 30, 106].
Hypothyroidism has also been linked to increased DCM rates in some studies. 
For example Doberman Pinchsers with DCM were 2.26 times more likely to have 
or develop hypothyroidism [107], and suggestions to links between the two condi-
tions was also proposed in two Great Dane individuals [108]. Some research has not 
necessarily shown a link between the two disorders [109–111], therefore there are 
still questions around links, especially causal ones. Although exact mechanisms, 
or indeed associations have yet to be determined, evidence does support that the 
thyroid hormones can have positive inotropic and chronotropic effects, and that 
under both experimental and in patients these may have important influences over 
cardiovascular health and functions [112].
5. Canines as a model for human cardiomyopathy
Current understanding of disease processes and treatments is based on studying 
affected individuals compared to unaffected individuals, along with the use of animal 
models of disease, cell lines, and computer simulations [113–119]. Natural models of 
disease allow researchers access to additional cases of disease without inducing dis-
ease and causing additional suffering, because the animals involved develop disease 
irrespective of involvement in a study. Therefore, a relevant resource for investigating 
health and disease is the companion animal population, within which dogs in particu-
lar are useful as natural models of the equivalent human disease [1, 120–123].
The canine population overall is genetically heterogeneous, yet breeds are com-
paratively homogeneous which enhances their value as genetic models of disease 
[124]. Each breed of dog is a closed population and ancestry can typically be traced 
for many generations, often to the founding members of the breed [124–126]. This 
facilitates understanding the mode of inheritance of traits and diseases, and also 
restricts the amount of genetic diversity within a breed [34, 121, 125, 127]. Founder 
effects and subsequent inbreeding within pedigree dog breeds have led to differing 
allele frequencies between breeds, and some breeds are more prone to developing 
particular conditions than others [124, 128, 129]. This makes breeds with homologs 
of human conditions ideal for identifying potential genetic loci associated with 
disease for both canine and human benefit [123, 130].
Many canine disease phenotypes can be closely matched to human disease 
phenotypes with similar disease progression, pathology, treatment options, and 
prognosis [78–80]. Indeed there are currently 383 potential canine models for 
human disease listed in OMIA (Online Mendelian Inheritance in Animals), greater 
than any other species [78, 79]. Dogs are typically treated as family members and so 
inhabit the same environment as their owners with the associated exposure to the 
same potential environmental toxins, including, for example, air pollution [131]. 
Pet dogs also frequently benefit from high quality medical care, such that illnesses 
are detected and treated promptly, similar to the human population [132]. These 
characteristics of the canine population make it a valuable resource as a model of 
human disease. Examples of diseases with homologies in humans and dogs include 
diabetes, cardiomyopathies, cancers, and eye diseases [79, 120, 123, 133, 134].
6. Conclusions
Diagnosis of disease is informed by patient symptoms, family history, medical 
testing, and in some cases genetic testing [135–137]. With greater understanding 
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of disease progression, these aspects can be more accurately assessed and give 
earlier accurate diagnoses [87]. Early diagnosis can enable early treatment, which 
can result in improved outcomes compared to patients diagnosed later in the 
disease course [87, 92, 138]. Screening for disease prior to the onset of symptoms 
can catch diseases at an early stage, but may not be useful or affordable for an 
entire population. Screening asymptomatic individuals can be recommended 
when there is an additional reason to suspect that an individual may develop dis-
ease, such as family/breed history of the disease or a genetic test result indicating 
susceptibility to disease [95, 96]. A positive genetic test result often does not fully 
predict disease development, but merely indicates that the individual has a genetic 
pre-disposition to developing the disease [139]. Thus, a positive genetic test result 
does not always result in direct medical intervention, yet it can lead to increased 
awareness of the disease and enrolment of the individual on a health monitoring 
programme [92, 96]. Not only can the dog be an excellent model, but lessons can 
also be learned from other species with DCM [61].
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